(2S)-2-[[2-(3,5-difluorophenyl)acetyl]amino]-N-[(3S)-2-oxo-1-[(3-phenoxyphenyl)methyl]azepan-3-yl]propanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[2-(3,5-difluorophenyl)acetyl]amino]-N-[(3S)-2-oxo-1-[(3-phenoxyphenyl)methyl]azepan-3-yl]propanamide
• 化学式: C₃₀H₃₁F₂N₃O₄
• 分子量: 535.6
• InChiKey: KBAGNMCXZKMTQK-DCFHFQCYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Lactams as inhibitors of A-beta protein production
  申请人：——

  公开号：US20020010172A1

  公开（公告）日：2002-01-24

  This invention relates to novel lactams having the Formula (I): 1 to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有式（I）的新型内酰胺，其制药组合物以及使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ-肽的生成，从而防止神经淀粉样蛋白沉积的形成。更具体地，本发明涉及与β-淀粉样蛋白生成相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。
• LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1267906A1

  公开（公告）日：2003-01-02
• US6495540B2
  申请人：——

  公开号：US6495540B2

  公开（公告）日：2002-12-17
• [EN] LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION<br/>[FR] LACTAMES EN TANT QU'INHIBITEURS DE PRODUCTION DE PROTEINES A-BETA
  申请人：DU PONT PHARM CO

  公开号：WO2001072324A1

  公开（公告）日：2001-10-04

  This invention relates to novel lactams having the Formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.